BACKGROUND AND PURPOSE: The β-receptor antagonist carvedilol blocks a range of ion channels. K2P 2.1 (TREK1) and K2P 10.1 (TREK2) channels are expressed in the heart and regulated by alternative translation initiation (ATI) of their mRNA, producing functionally distinct channel variants. The first objective was to investigate acute effects of carvedilol on human K2P 2.1 and K2P 10.1 channels. Second, we sought to study ATI-dependent modulation of K2P K(+) current sensitivity to carvedilol. EXPERIMENTAL APPROACH: Using standard electrophysiological techniques, we recorded currents from wild-type and mutant K2P 2.1 and K2P 10.1 channels in Xenopus oocytes and HEK 293 cells. KEY RESULTS: Carvedilol concentration-dependently inhibited K2P 2.1 channels (IC50 ,oocytes = 20.3 μM; IC50 , HEK = 1.6 μM) and this inhibition was frequency-independent. When K2P 2.1 isoforms generated by ATI were studied separately in oocytes, the IC50 value for carvedilol inhibition of full-length channels (16.5 μM) was almost 5-fold less than that for the truncated channel variant (IC50 = 79.0 μM). Similarly, the related K2P 10.1 channels were blocked by carvedilol (IC50 ,oocytes = 24.0 μM; IC50 , HEK = 7.6 μM) and subject to ATI-dependent modulation of drug sensitivity. CONCLUSIONS AND IMPLICATIONS: Carvedilol targets K2P 2.1 and K2P 10.1 K(+) channels. This previously unrecognized mechanism supports a general role of cardiac K2P channels as antiarrhythmic drug targets. Furthermore, the work reveals that the sensitivity of the cardiac ion channels K2P 2.1 and K2P 10.1 to block was modulated by alternative mRNA translation initiation.
BACKGROUND AND PURPOSE: The β-receptor antagonist carvedilol blocks a range of ion channels. K2P 2.1 (TREK1) and K2P 10.1 (TREK2) channels are expressed in the heart and regulated by alternative translation initiation (ATI) of their mRNA, producing functionally distinct channel variants. The first objective was to investigate acute effects of carvedilol on humanK2P 2.1 and K2P 10.1 channels. Second, we sought to study ATI-dependent modulation of K2P K(+) current sensitivity to carvedilol. EXPERIMENTAL APPROACH: Using standard electrophysiological techniques, we recorded currents from wild-type and mutant K2P 2.1 and K2P 10.1 channels in Xenopus oocytes and HEK 293 cells. KEY RESULTS:Carvedilol concentration-dependently inhibited K2P 2.1 channels (IC50 ,oocytes = 20.3 μM; IC50 , HEK = 1.6 μM) and this inhibition was frequency-independent. When K2P 2.1 isoforms generated by ATI were studied separately in oocytes, the IC50 value for carvedilol inhibition of full-length channels (16.5 μM) was almost 5-fold less than that for the truncated channel variant (IC50 = 79.0 μM). Similarly, the related K2P 10.1 channels were blocked by carvedilol (IC50 ,oocytes = 24.0 μM; IC50 , HEK = 7.6 μM) and subject to ATI-dependent modulation of drug sensitivity. CONCLUSIONS AND IMPLICATIONS: Carvedilol targets K2P 2.1 and K2P 10.1 K(+) channels. This previously unrecognized mechanism supports a general role of cardiac K2P channels as antiarrhythmic drug targets. Furthermore, the work reveals that the sensitivity of the cardiac ion channels K2P 2.1 and K2P 10.1 to block was modulated by alternative mRNA translation initiation.
Authors: Ann-Kathrin Rahm; Jakob Gierten; Jana Kisselbach; Ingo Staudacher; Kathrin Staudacher; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: C Seyler; E Duthil-Straub; E Zitron; J Gierten; E P Scholz; R H A Fink; C A Karle; R Becker; H A Katus; D Thomas Journal: Br J Pharmacol Date: 2012-03 Impact factor: 8.739
Authors: M Takusagawa; S Komori; K Matsumura; M Osada; I Kohno; K Umetani; T Ishihara; T Sawanobori; H Ijiri; K Tamura Journal: J Cardiovasc Pharmacol Ther Date: 2000-04 Impact factor: 2.457
Authors: Stella Petric; Lukas Clasen; Carina van Wessel; Nora Geduldig; Zhaoping Ding; Martina Schullenberg; Jan Mersmann; Kai Zacharowski; Maria I Aller; Klaus G Schmidt; Birgit C Donner Journal: Cell Physiol Biochem Date: 2012-07-19
Authors: A D Medhurst; G Rennie; C G Chapman; H Meadows; M D Duckworth; R E Kelsell; I I Gloger; M N Pangalos Journal: Brain Res Mol Brain Res Date: 2001-01-31
Authors: Constanze Schmidt; Felix Wiedmann; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-07-13 Impact factor: 3.000
Authors: Felix Wiedmann; Daniel Schlund; Francisco Faustino; Manuel Kraft; Antonius Ratte; Dierk Thomas; Hugo A Katus; Constanze Schmidt Journal: Int J Mol Sci Date: 2019-10-20 Impact factor: 5.923
Authors: Stefan Just; Bertrand L Chenard; Angelo Ceci; Timothy Strassmaier; Jayhong A Chong; Nathaniel T Blair; Randall J Gallaschun; Donato Del Camino; Susan Cantin; Marc D'Amours; Christian Eickmeier; Christopher M Fanger; Carsten Hecker; David P Hessler; Bastian Hengerer; Katja S Kroker; Sam Malekiani; Robert Mihalek; Joseph McLaughlin; Georg Rast; JoAnn Witek; Achim Sauer; Christopher R Pryce; Magdalene M Moran Journal: PLoS One Date: 2018-01-31 Impact factor: 3.240